Liquid Biopsies, What We Do Not Know (Yet)
Liquid Biopsies, What We Do Not Know (Yet)
复制标题
DOI：
10.1016/j.ccell.2017.01.002
复制
发表时间：
2017-02-13
期刊：
影响因子：
50.3
通讯作者：
Pantel, Klaus
中科院分区：
文献类型：
--
作者：
Bardelli, Alberto;Pantel, Klaus
转移性肿瘤固有的分子异质性以及癌症基因组动态演变的能力无法通过组织样本得到恰当体现。对无细胞DNA和循环肿瘤细胞的分析有可能通过利用血液而非组织作为信息来源来改变临床实践。液体活检已经被用于监测疾病反应以及追踪耐药性的产生。基于血液的分子图谱对早期检测和监测微小残留疾病的适用性正在接受评估。在这篇综述中，我们探讨了这个快速发展的研究领域中尚未解决的问题。
The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.